開源控股(01215.HK)建議採納新購股權計劃
格隆匯5月16日丨開源控股(01215.HK)發佈公吿,2012年5月17日,集團根據股東的普通決議案採納一項購股權計劃。現有購股權計劃的期限自其採納日期起為期10年,並將於2022年5月16日期滿。現有購股權計劃期滿後,將不會進一步提呈購股權。截至該公吿日期,根據現有購股權計劃仍未行使的購股權可認購公司144,780,000股股份,佔公司已發行股本約1.13%。
鑑於現有購股權計劃期滿,公司董事會建議採納新購股權計劃,並將於2022年6月2日舉行的應屆股東周年大會上提呈普通決議案,以尋求股東批准採納新購股權計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.